Vir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
Oct 14 (Reuters) — Vir Biotechnology said on Wednesday it had signed a collaboration agreement worth up to $1.88 billion with Gilead Sciences to discover and develop new cancer treatments for solid tumors. Shares of Vir rose more than 10% in premarket trading following the announcement. Under the agreement, Vir will re